Michela Guida

Ms. Michela Guida

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CTCHIARA TAMMARO
CHIARA TAMMARO
MGMichela Guida
Michela Guida
Federico AppetecchiaFederico Appetecchia
Federico Appetecchia
Mariangela BiavaMariangela Biava
Mariangela Biava
SCSara Consalvi
Sara Consalvi
GPGiovanna Poce
Giovanna Poce
Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market. As their clinical relevance has become more serious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antivirals with very high selectivity indexes and promising in vitro activities have been discovered. The scope of this review encompasses recent advances in the discovery of new compounds with anti-viral activity against EV-B, as well as further progress in repurposing drugs to treat these infections. Current progress and future perspectives in drug discovery against EV-Bs are briefly discussed and existing gaps are spotlighted.

28 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MGMichela Guida
Michela Guida
CTCHIARA TAMMARO
CHIARA TAMMARO
MQMiriana Quaranta
Miriana Quaranta
BSBenedetta Salvucci
Benedetta Salvucci
Mariangela BiavaMariangela Biava
Mariangela Biava
SCSara Consalvi
Sara Consalvi
According to the latest World Health Organization (WHO) report, an estimated 10.6 million people were diagnosed with tuberculosis (TB) in 2022, and 1.30 million died. A major concern is the emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) strains, fueled by the length of anti-TB treatment and HIV comorbidity. Innovative anti-TB agents acting with new modes of action are the only solution to counteract the spread of resistant infections. To escape starvation and survive inside macrophages, Mtb has evolved to become independent of the host by synthesizing its own amino acids. Therefore, targeting amino acid biosynthesis could subvert the ability of the mycobacterium to evade the host immune system, providing innovative avenues for drug discovery. The aim of this review is to give an overview of the most recent progress in the discovery of amino acid biosynthesis inhibitors. Among the hits discovered over the past five years, tryptophan (Trp) inhibitors stand out as the most advanced and have significantly contributed to demonstrating the feasibility of this approach for future TB drug discovery. Future efforts should be directed at prioritizing the chemical optimization of these hits to enrich the TB drug pipeline with high-quality leads.

3 October 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AOAbraham Oluwole
Abraham Oluwole
NKNeha V. Kalmankar
Neha V. Kalmankar
MGMichela Guida
Michela Guida
JBJack L. Bennett
Jack L. Bennett
GPGiovanna Poce
Giovanna Poce
CRCarol V. Robinson
Carol V. Robinson
The peptidoglycan pathway represents one of the most successful antibacterial targets with the last critical step being the flipping of carrier lipid, undecaprenyl phosphate (C 55 -P), across the membrane to reenter the pathway. This translocation of C 55 -P is facilitated by DedA and DUF368 domain-containing family membrane proteins via unknown mechanisms. Here, we employ native mass spectrometry to investigate the interactions of UptA, a member of the DedA family of membrane protein from Bacillus subtilis , with C 55 -P, membrane phospholipids, and cell wall-targeting antibiotics. Our results show that UptA, expressed and purified in Escherichia coli , forms monomer–dimer equilibria, and binds to C 55 -P in a pH-dependent fashion. Specifically, we show that UptA interacts more favorably with C 55 -P over shorter-chain analogs and membrane phospholipids. Moreover, we demonstrate that lipopeptide antibiotics, amphomycin and aspartocin D, can directly inhibit UptA function by out-competing the substrate for the protein binding, in addition to their propensity to form complex with free C 55 -P. Overall, this study shows that UptA-mediated translocation of C 55 -P is potentially mediated by pH and anionic phospholipids and provides insights for future development of antibiotics targeting carrier lipid recycling.

18 November 2024 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
SBSalvucci Benedetta
Salvucci Benedetta
FVFrancesco Vallini
Francesco Vallini
MGMichela Guida
Michela Guida
CTCHIARA TAMMARO
CHIARA TAMMARO
MBMariangela Biava
Mariangela Biava
GPGiovanna Poce
Giovanna Poce
IntroductionTuberculosis (TB) remains a major global health issue, causing around 10 million new cases and 1.3 million deaths in 2022. The challenge is compounded by multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains, and co-infection with HIV.Areas coveredThe present review examines significant patent literature on TB chemotherapeutics from September 2021 to the present using the following databases, reaxys, google patent and espacenet. Only patents reporting compounds with a minimum inhibitory concentration (MIC) on whole Mycobacterium tuberculosis cells of <= 5 mu M were selected for review.Expert opinionThe fight against TB is advancing with the development of promising new compounds due to the challenge of drug-resistant strains. Notable among those reviewed in this paper are the benzothiazinones, showing high efficacy against both drug-sensitive and resistant TB strains. Additionally, Q203 analogues, demonstrate strong antitubercular activity, good microsomal stability, and favorable safety profiles. Finally, LysRS inhibitors also show significant promise in vivo models. These advancements underscore the importance of novel targets and innovative strategies in developing effective, resistance-resistant TB treatments.

7 October 2025 in ACS Infectious Diseases
Verified
Journal Article
Open access
RGRoberto Gimmelli
Roberto Gimmelli
GPGiuliana Papoff
Giuliana Papoff
EFEmanuele Fabbrizi
Emanuele Fabbrizi
MGMichela Guida
Michela Guida
CLCristiana Lalli
Cristiana Lalli
GRGiovina Ruberti
Giovina Ruberti
Schistosomiasis, a neglected tropical disease caused by trematodes of Schistosoma genus, urgently requires new treatments due to praziquantel's limited efficacy against juvenile worms as well as the threat of drug resistance. In this study, we evaluated a series of benzodeazaoxaflavin (BDF4)-based compounds as inhibitors of the parasite's epigenetic enzyme SmSirt2. Three compounds, 7-9 (MC2346, MC2141, and MC2345), showed activity against both Liberian and Puerto Rican strains of Schistosoma mansoni. The compounds reduced schistosomula and adult worm pair viability, pairing, and egg production, with low cytotoxicity in mammalian cells. These effects were linked to histone H3 hyperacetylation and cytochrome c-mediated apoptosis, confirming SmSirt2 as a functional target. These findings support the development of SmSirt2 inhibitors as novel antischistosomal agents with therapeutic potential for both curative and preventive applications. Further in vivo studies are warranted to assess their pharmacokinetic and safety profiles.

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
EMErnesto Maddaloni
Ernesto Maddaloni
KPKyoungmin Park
Kyoungmin Park
MGMichela Guida
Michela Guida
LCLucia Coraggio
Lucia Coraggio
CLCecilia Luordi
Cecilia Luordi
RBRaffaella Buzzetti
Raffaella Buzzetti
Novel markers of vascular disease in diabetes could help identify new disease pathways and enhance risk stratification. Osteoprotegerin (OPG) and osteopontin (OPN) are key molecules involved in bone and vascular calcification processes, both compromised in diabetes. To evaluate whether OPG and/or OPN are associated with diabetic vascular complications, we measured their serum concentrations in 995 type 2 diabetes subjects enrolled in the Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study. Any association with history of cardiovascular disease (CVD), diabetic retinopathy (DR) and reduced eGFR were examined with ANOVA, correcting for age, gender, HbA1c and lipid profile. Among the population, 15.7% had CVD, 18.4% had DR, 12.0% had an eGFR between 45-59 ml/min/1.73m2 and 7.5% had an eGFR <45 ml/min/1.73m2. Serum OPG, but OPN, concentrations stratified according to the presence of CVD, DR or reduced eGFR (p<0.001). Specifically, OPG levels were higher in patients with than in those without CVD (median [IQR]: 11.5 [11.7] vs.10.0 [9.5], p=0.004) or DR (13.3 [14.7] vs.9.7 [8.9], p<0.001), and in patients with an eGFR <45 ml/min/1.73m2 (17.0 [23.5]) compared with an eGFR 45-59 ml/min/1.73m2 (13.2 [13.5]) and ≥60 ml/min/1.73m2 (9.4 [8.7] (p <0.001).To explore potential mechanisms for the association of vascular complications with OPG and/or OPN, we assessed insulin-mediated eNOS activity in bovine aortic endothelial cells cultures (BAECs) with OPG or OPN in the presence of insulin. OPG, but not OPN, inhibited insulin-induced eNOS activation in a dose-dependent manner. Additionally, OPG inhibited insulin-induced activation of both pERK and pAKT in BAECs. In summary, our results show that OPG associates with vascular disease in diabetes and suggest that this effect is mediated by endothelial insulin-resistance and reduced insulin-induced NO production. Disclosure E. Maddaloni: Consultant; Self; Merck KGaA. Speaker’s Bureau; Self; Abbott, AstraZeneca, Pikdare. K. Park: None. M. Di Guida: None. L. Coraggio: None. C. Luordi: None. L. D’Onofrio: None. M.G. Baroni: None. M.G. Cavallo: None. P. D’Angelo: None. S. De Cosmo: None. F. Leonetti: None. S. Morano: None. L. Morviducci: None. P. Pozzilli: Advisory Panel; Self; Abbott, AstraZeneca, Eli Lilly and Company. Research Support; Self; Medtronic, Sanofi. S. Prudente: None. G. Pugliese: Advisory Panel; Self; Novo Nordisk A/S. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Mundipharma International, Sanofi-Aventis, Sigma-tau, Takeda Pharmaceutical Company Limited. Other Relationship; Self; Laboratori Guidotti. V. Trischitta: None. R.R. Holman: Advisory Panel; Self; Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S. Research Support; Self; AstraZeneca, Bayer AG, Merck Sharp & Dohme Corp. G.L. King: Research Support; Self; Janssen Pharmaceuticals, Inc. R. Buzzetti: Advisory Panel; Self; Sanofi. Speaker’s Bureau; Self; AstraZeneca, Lilly Diabetes, Merck Sharp & Dohme Corp. Funding European Foundation for the Study of Diabetes; AstraZeneca (MS 2017_2); Società Italiana di Diabetologia